RxDoctor Payments Data

Libro Oniboni, DO

Family Medicine · Saxonburg, PANPI 1619983509

Payments from drug & device makers

$2,244in general payments, 2019–2025

Across 160 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$369
  • Novo Nordisk$363
  • AstraZeneca$219
  • Boehringer Ingelheim$204
  • Lilly USA, LLC$195
  • Amgen$162
  • plus $732 from 13 others

What the payments were for

  • Food & beverage$2,244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,244 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,396
Medicare patients
103
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$76,762
OzempicSemaglutide54$56,258
JardianceEmpagliflozin40$47,453
JanuviaSitagliptin Phosphate38$42,174
MounjaroTirzepatide27$39,666
XareltoRivaroxaban29$28,505
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,038
TrulicityDulaglutide22$20,233
MultaqDronedarone Hcl16$18,731
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$16,324
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$13,090
Breo ElliptaFluticasone/Vilanterol26$11,881
LivaloPitavastatin Calcium15$5,322
SynthroidLevothyroxine Sodium69$4,611
PaxlovidNirmatrelvir/Ritonavir12$4,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$71$81,049104 claims
Lilly USA, LLCMounjaro, Trulicity$195$59,89949 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$369$58,10989 claims
Novo NordiskOzempic$363$56,25854 claims
Boehringer IngelheimJardiance$204$47,45340 claims
MerckJanuvia$126$42,17438 claims
Kowa Pharmaceuticals America, Inc.Livalo$125$5,32215 claims
AbbVieSynthroid$41$4,61169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Saxonburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →